Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and Parkinson's disease
Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and Parkinson's disease
复制标题
DOI：
10.1016/j.schres.2014.11.010
复制
发表时间：
2015-02-01
影响因子：
4.5
通讯作者：
Llorca, P. M.
中科院分区：
文献类型：
--
作者：
de Chazeron, I.;Pereira, B.;Llorca, P. M.
目的：如果幻觉是最常见的精神分裂症症状，他们已被描述在其他病理，如帕金森氏病（PD），但可能有很大的不同，在他们的现象。然而，没有多模态临床量表与transnosographic方法已经开发出来。本研究的目的是创建和验证一个新的工具，异源评估的所有感觉方式的幻觉精神分裂症（SCZ）和PD。方法：量表项目产生的文献综述和医学委员会的验证。然后对心理-感觉幻觉量表（PSAS）的四个维度进行了心理测量学研究结果：在137例患者中验证了该量表：86例PD患者中有86例PD患者在137例PD患者中验证了该量表，其中86例PD患者在137例PD患者中验证了该量表。（53.5%男性;平均年龄= 53.3岁）和51例SCZ（64.7%男性;平均年龄= 38.5岁）。PSAS的因子分析发现四个因素。PSAS显示出良好的内部一致性[Kuder-Richardson α系数0.49至0.77]和良好的重测信度[一致性% = 0.75至0.97]和评定者间信度[一致性% = 0.78至1.0]。PSAS与PANSS P3、PANSS RS 1 I2概念的一致性效度表明PSAS与PANSS P3、PANSS RS 1 I2概念的一致性评价。结论：PSAS可用于描述精神分裂症和PD患者的幻觉及其在病程和治疗过程中的演变。此外，它可以让我们对这两种疾病的幻觉模式进行临床病理比较，以提高我们对其精确神经机制的理解。(C)2014爱思唯尔有限公司版权所有。
Objective: If hallucinations are the most common of schizophrenic symptoms, they have been described in other pathologies such as Parkinson's disease (PD) but may differ considerably in their phenomenology. However, no multi-modal clinical scale with a transnosographic approach has been developed today. The purpose of this study was to create and validate a new tool for the hetero-assessment of all sensory modalities of hallucinations schizophrenia (SCZ) and in PD.Method: Scale items were generated by literature review and validated by medical board. A study was then made to evaluate psychometric properties of the Psycho-Sensory hAllucinations Scale (PSAS) that include four domains (auditory, visual, olfactory and gustatory, cenesthetic modalities) and one specific item 'guardian angel'.Results: It was then validated in 137 patients: 86 PD (53.5% male; mean age = 53.3 years) and 51 SCZ (64.7% male; mean age = 38.5 years). Factorial analysis of the PSAS found four factors. The PSAS showed good internal consistency [Kuder-Richardson alpha coefficient 0.49 to 0.77] and good test-retest reliability [Agreement % = 0.75 to 0.97] and inter-rater reliability [Agreement % = 0.78 to 1.0]. The convergent validity illustrates the concomitant evaluation of the concept between PSAS and PANSS P3 and UPDRS1 I2.Conclusion: The PSAS can be useful to describe the whole hallucination and its evolution during the course of the disease and treatment in schizophrenia and PD. Moreover, it can allow us to undertake a clinic-pathological comparison of hallucination modalities between these two diseases, to enhance our understanding of their precise neurological mechanisms. (C) 2014 Elsevier B.V. All rights reserved.